Healthcare cost and survival in patients with non-functioning pituitary adenoma
Authors' conclusion
This healthcare utilization study identified several factors driving the cost of care in NFPA patients, such as GH replacement, adrenal insufficiency, and diabetes insipidus. Life expectancy was increased in those with GH replacement and reduced in patients with adrenal insufficiency and diabetes insipidus.
Study context
- Population
- All patients with non-functioning pituitary adenoma (NFPA), Västra Götaland region, Sweden, followed from 1987 or diagnosis until death or December 31, 2019; 274 men; follow-up 13.6 ± 6.8 years (mean ± SD)274 men
- Participants
- 426 patients
- Exposure
- Growth hormone (GH) replacement vs no GH replacement
- Outcome
- Total annual healthcare cost
Methodological detailspopulation-based, regional/national healthcare registries
- Population-based
- Regional/national healthcare registries
Main finding
As reported in the abstract
GH
€9287
No GH
€6770
Observational data: associations, not effects.
Further findings
| Outcome | HR | P value |
|---|---|---|
| SurvivalSurvival rate higher with GH | 0.60 | P = 0.01 |
Survival by glucocorticoid replacement and diabetes insipidus
- Glucocorticoid replacement, survival reduced: HR, event not stated
- 2.02; P < .01
- Diabetes insipidus, survival reduced: HR, event not stated
- 1.67; P = .04
Factors individually associated with higher total annual cost
- Glucocorticoid replacement therapy
- P = 0.02
- Diabetes insipidus
- P = 0.04
- Body mass index (BMI)
- P < 0.01
- Hypertension
- P < 0.01
Cost-effectiveness: cost per gained life-year, GH vs no GH
- Cost per gained life-year
- about €37 000
Original publication
Healthcare cost and survival in patients with non-functioning pituitary adenoma. Eur J Endocrinol. Published 26 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →